Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register

for the START-Laboratory Register

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Several specific assays are commercially available to determine dabigatran anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five methods for dabigatran measurement and investigate their performances in the low concentration range. Methods: Dabigatran levels were analyzed in 295 plasma samples from patients enrolled in the START-Laboratory Register by the following methods using dedicated calibrators and controls: STA-ECA II (Diagnostica Stago), standard and low range Hemoclot Thrombin Inhibitors (Hyphen BioMed), Direct Thrombin Inhibitor Assay (Instrumentation Laboratory), Direct Thrombin Inhibitor Assay (Siemens), Technoclot DTI (Technoclone). Results: Methods showed variable agreement with the Hemoclot Thrombin Inhibitors assay used as reference test, with modest under- or overestimations (Bland-Altman bias from −17.3 to 4.0 ng/mL). Limits of detection and quantification varied depending on the assay (4-52 and 7-82 ng/mL, respectively). Between-run precision and accuracy were good for all methods for both quality control levels. Assay's repeatability assessed at very low dabigatran concentrations (from 10 to 60 ng/mL) was also acceptable, variability generally increased at lower drug levels. Conclusion: The five dabigatran-specific assays evaluated in this study provided reliable assessment of dabigatran plasma levels, although showing different performances.

Original languageEnglish
Pages (from-to)229-236
Number of pages8
JournalInternational Journal of Laboratory Hematology
Volume40
Issue number2
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Assays
Plasmas
Antithrombins
Thrombin
Quality Control
Anticoagulants
Multicenter Studies
Limit of Detection
Dabigatran
Quality control
Pharmaceutical Preparations

Keywords

  • chromogenic assay
  • clotting assay
  • dabigatran
  • direct thrombin inhibitor
  • laboratory testing

ASJC Scopus subject areas

  • Hematology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register. / for the START-Laboratory Register.

In: International Journal of Laboratory Hematology, Vol. 40, No. 2, 01.04.2018, p. 229-236.

Research output: Contribution to journalArticle

@article{132fc56e93e34ac7bed33b4f2c83bf86,
title = "Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register",
abstract = "Introduction: Several specific assays are commercially available to determine dabigatran anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five methods for dabigatran measurement and investigate their performances in the low concentration range. Methods: Dabigatran levels were analyzed in 295 plasma samples from patients enrolled in the START-Laboratory Register by the following methods using dedicated calibrators and controls: STA-ECA II (Diagnostica Stago), standard and low range Hemoclot Thrombin Inhibitors (Hyphen BioMed), Direct Thrombin Inhibitor Assay (Instrumentation Laboratory), Direct Thrombin Inhibitor Assay (Siemens), Technoclot DTI (Technoclone). Results: Methods showed variable agreement with the Hemoclot Thrombin Inhibitors assay used as reference test, with modest under- or overestimations (Bland-Altman bias from −17.3 to 4.0 ng/mL). Limits of detection and quantification varied depending on the assay (4-52 and 7-82 ng/mL, respectively). Between-run precision and accuracy were good for all methods for both quality control levels. Assay's repeatability assessed at very low dabigatran concentrations (from 10 to 60 ng/mL) was also acceptable, variability generally increased at lower drug levels. Conclusion: The five dabigatran-specific assays evaluated in this study provided reliable assessment of dabigatran plasma levels, although showing different performances.",
keywords = "chromogenic assay, clotting assay, dabigatran, direct thrombin inhibitor, laboratory testing",
author = "{for the START-Laboratory Register} and M. Cini and C. Legnani and B. Cosmi and S. Testa and C. Dellanoce and O. Paoletti and R. Marcucci and D. Poli and R. Paniccia and V. Pengo and A. Tripodi and G. Palareti",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/ijlh.12772",
language = "English",
volume = "40",
pages = "229--236",
journal = "International Journal of Laboratory Hematology",
issn = "1751-5521",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register

AU - for the START-Laboratory Register

AU - Cini, M.

AU - Legnani, C.

AU - Cosmi, B.

AU - Testa, S.

AU - Dellanoce, C.

AU - Paoletti, O.

AU - Marcucci, R.

AU - Poli, D.

AU - Paniccia, R.

AU - Pengo, V.

AU - Tripodi, A.

AU - Palareti, G.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Introduction: Several specific assays are commercially available to determine dabigatran anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five methods for dabigatran measurement and investigate their performances in the low concentration range. Methods: Dabigatran levels were analyzed in 295 plasma samples from patients enrolled in the START-Laboratory Register by the following methods using dedicated calibrators and controls: STA-ECA II (Diagnostica Stago), standard and low range Hemoclot Thrombin Inhibitors (Hyphen BioMed), Direct Thrombin Inhibitor Assay (Instrumentation Laboratory), Direct Thrombin Inhibitor Assay (Siemens), Technoclot DTI (Technoclone). Results: Methods showed variable agreement with the Hemoclot Thrombin Inhibitors assay used as reference test, with modest under- or overestimations (Bland-Altman bias from −17.3 to 4.0 ng/mL). Limits of detection and quantification varied depending on the assay (4-52 and 7-82 ng/mL, respectively). Between-run precision and accuracy were good for all methods for both quality control levels. Assay's repeatability assessed at very low dabigatran concentrations (from 10 to 60 ng/mL) was also acceptable, variability generally increased at lower drug levels. Conclusion: The five dabigatran-specific assays evaluated in this study provided reliable assessment of dabigatran plasma levels, although showing different performances.

AB - Introduction: Several specific assays are commercially available to determine dabigatran anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five methods for dabigatran measurement and investigate their performances in the low concentration range. Methods: Dabigatran levels were analyzed in 295 plasma samples from patients enrolled in the START-Laboratory Register by the following methods using dedicated calibrators and controls: STA-ECA II (Diagnostica Stago), standard and low range Hemoclot Thrombin Inhibitors (Hyphen BioMed), Direct Thrombin Inhibitor Assay (Instrumentation Laboratory), Direct Thrombin Inhibitor Assay (Siemens), Technoclot DTI (Technoclone). Results: Methods showed variable agreement with the Hemoclot Thrombin Inhibitors assay used as reference test, with modest under- or overestimations (Bland-Altman bias from −17.3 to 4.0 ng/mL). Limits of detection and quantification varied depending on the assay (4-52 and 7-82 ng/mL, respectively). Between-run precision and accuracy were good for all methods for both quality control levels. Assay's repeatability assessed at very low dabigatran concentrations (from 10 to 60 ng/mL) was also acceptable, variability generally increased at lower drug levels. Conclusion: The five dabigatran-specific assays evaluated in this study provided reliable assessment of dabigatran plasma levels, although showing different performances.

KW - chromogenic assay

KW - clotting assay

KW - dabigatran

KW - direct thrombin inhibitor

KW - laboratory testing

UR - http://www.scopus.com/inward/record.url?scp=85043594769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043594769&partnerID=8YFLogxK

U2 - 10.1111/ijlh.12772

DO - 10.1111/ijlh.12772

M3 - Article

AN - SCOPUS:85043594769

VL - 40

SP - 229

EP - 236

JO - International Journal of Laboratory Hematology

JF - International Journal of Laboratory Hematology

SN - 1751-5521

IS - 2

ER -